Summary
The global osteoporosis drugs market size reached US$ 15.1 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 20.4 Billion by 2027, exhibiting a growth rate (CAGR) of 5.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.
The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.
Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type and route of administration.
Breakup by Product Type:
Bisphosphonates
Calcitonin
Rank Ligand Inhibitor
Parathyroid Hormone Therapy (PTH)
Selective Estrogen Receptor Modulators (SERMs)
Sclerostin Inhibitor
Others
Breakup by Route of Administration:
Oral
Injectable
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.
Key Questions Answered in This Report:
How has the global osteoporosis drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global osteoporosis drugs market?
What are the key regional markets?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the route of administration?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global osteoporosis drugs market and who are the key players?
What is the degree of competition in the industry?
